在新生血管性年龄相关性黄斑变性中从按需治疗方案转换为使用阿柏西普的治疗并延长方案时的疗效
Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration.
作者信息
Giannakaki-Zimmermann Helena, Ebneter Andreas, Munk Marion R, Wolf Sebastian, Zinkernagel Martin S
机构信息
Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
出版信息
Ophthalmologica. 2016;236(4):201-206. doi: 10.1159/000452929. Epub 2016 Dec 2.
PURPOSE
To investigate outcomes in patients with neovascular age-related macular degeneration (AMD) switched from a pro re nata regimen (PRN) to a treat and extend regimen (TER) under aflibercept.
PROCEDURE
Thirty-two patients were observed over 2 years: the first year on PRN and the second year on TER. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were evaluated. Intra- and subretinal fluid as well as the number of visits and injections were assessed.
RESULTS
Both regimens resulted in a stable BCVA. Patients in TER had a significant decrease of CRT after 1 year compared to 1 year of treatment on PRN (p < 0.0001). TER resulted in significantly less visits; however, significantly more injections were observed over the course of 1 year compared to PRN (10.25 vs. 7.5, p < 0.0001 and 5.97 vs. 7.5, p = 0.0002, respectively).
CONCLUSION
A switch from PRN to TER in patients treated with aflibercept for AMD appears to be safe.
目的
研究接受阿柏西普治疗的新生血管性年龄相关性黄斑变性（AMD）患者从按需给药方案（PRN）转换为治疗并延长方案（TER）后的治疗效果。
方法
对32例患者进行了为期2年的观察：第一年采用PRN方案，第二年采用TER方案。评估最佳矫正视力（BCVA）和视网膜中央厚度（CRT）。评估视网膜内和视网膜下液以及就诊次数和注射次数。
结果
两种方案均使BCVA保持稳定。与接受PRN方案治疗1年相比，接受TER方案治疗1年后患者的CRT显著降低（p < 0.0001）。TER方案导致就诊次数显著减少；然而，与PRN方案相比，在1年的治疗过程中观察到注射次数显著增多（分别为10.25次对7.5次，p < 0.0001；5.97次对7.5次，p = 0.0002）。
结论
在接受阿柏西普治疗的AMD患者中，从PRN方案转换为TER方案似乎是安全的。
Zotero 插件